New hope for advanced colon cancer: drug duo targets tumors
NCT ID NCT07355764
First seen Feb 01, 2026 · Last updated Jun 08, 2026 · Updated 14 times
Summary
This study tests a new drug combination (SHR-1811 plus bevacizumab) as a second-line treatment for people with metastatic colorectal cancer that has worsened after initial therapy. About 80 adults aged 18-75 will participate. The goal is to see if the combo shrinks tumors and delays cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TARGETED THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.